# ATORVALIQ
> **NDA213260** · New Drug Application · Sponsor: CMP DEV LLC · Approved 2023-02-01
## Drug
- **FDA Application Number:** NDA213260
- **Application type:** New Drug Application
- **Brand name:** ATORVALIQ
- **Generic name:** ATORVALIQ
- **Active ingredients:** ATORVASTATIN CALCIUM
- **Dosage form:** SUSPENSION
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** CMP DEV LLC
- **Manufacturer:** CMP Pharma, Inc.
- **First approval:** 2023-02-01
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213260)
---
*AI Analytics · CC0 1.0*